Catalogue Search | MBRL
Are you sure you want to remove the book from the shelf?
{{itemTitle}}
12
result(s) for
"Pharmaceutical industry United States Corrupt practices"
Sort by:
No more tears : the secret history of Johnson & Johnson
\"When reporter Gardiner Harris met a woman at an airport bar whose entire family has been shattered by her nephew's use of the drug Risperdal, one she sold to his doctor as a drug sales rep, he began to wonder how many similar stories are out there. This was in 2004, and since then, Harris has been investigating one of the largest players in Big Pharma, continuously reporting on it despite simultaneous landmark journalistic accomplishments, like exposing the extremely toxic mining conditions ignored by coal companies. For decades, pharmaceutical giant Johnson & Johnson was seen as a paragon of ethical conduct, especially considering the company's child-friendly products like baby powder and tearless shampoo. However, Harris has uncovered reams of evidence of deceitful and dangerous corporate practices that reveal a historic threat to the health of the American public. He covers several disasters: tissue death caused by J & J's touted hip replacements, their coverup of baby powder's linkage to cancer, the teen-directed marketing of the life-altering drug Risperdal, and more. The Hatch-Waxman Bill, which is meant to pave the way for lower-priced generic drugs, passed in 1984, and inadvertently created loopholes in the drug approval process which allowed urgency and profit maximization to take precedence over diligence and patient protection. Johnson & Johnson's subsequent lack of oversight, money-grubbing, and flat out lies have resulted in the death or serious injury of millions of people. To many, the peril of falsified science seems distant, but Harris reveals how a combination of misrepresented data and bribe culture directly impact doctors' decisions-which are devastatingly revealed to be not at all in the interests of patients\"-- Provided by publisher.
BOOK
On the take : how medicine's complicity with big business can endanger your health
We all know that doctors accept gifts from drug companies, ranging from pens and coffee mugs to free vacations at luxurious resorts. But as this book exposes, these innocuous-seeming gifts are just the tip of an iceberg that is distorting the practice of medicine and jeopardizing the health of millions of Americans today. This book offers an unsettling look at the pervasive payoffs that physicians take from big drug companies and other medical suppliers, arguing that the billion-dollar onslaught of industry money has deflected many physicians' moral compasses and directly impacted the everyday care we receive from the doctors and institutions we trust most. Underscored by countless chilling untold stories, the book illuminates the financial connections between the wealthy companies that make drugs and the doctors who prescribe them. The book details the shocking extent of these financial enticements and explains how they encourage bias, promote dangerously misleading medical information, raise the cost of medical care, and breed distrust.
eBook
Profits before people? : ethical standards and the marketing of prescription drugs
The pharmaceutical industry has come under intense criticism in recent
years. One poll found that 70% of the sample agreed that drug companies put profits
ahead of people. Is this perception accurate? Have drug companies traded ethics for
profits and placed people at risk? In Profits before People?
Leonard J. Weber exposes pharmaceutical industry practices that have raised ethical
concerns. Providing systematic ethical analysis and reflection, he discusses such
practices as compensating physicians for serving as speakers or consultants,
providing incentives to physicians to enroll patients as subjects in clinical
research, and advertising prescription drugs to the public through the mass media.
Weber's critique of the industry is stern. While acknowledging that new industry
guidelines are promising, he finds much room for improvement in the way drug
companies market their products. Yet Weber makes a strong case that profits and
ethics can coexist and that they are not mutually exclusive. In an
effort to understand the proper place of commerce in disseminating information about
new drugs, the book aims to clarify basic responsibilities and to help identify
sound ethical practices. It recognizes that ethics and law are not the same, that
having a right is different from doing the right thing, and
that taking ethics seriously means recognizing that the law does not answer all
questions about what is right. Weber points the way to more demanding standards and
better practices that might begin to restore confidence in the drug
industry.
eBook
Psychiatry under the Influence
Psychiatry Under the Influence investigates the actions and practices of the American Psychiatric Association and academic psychiatry in the United States, and presents it as a case study of institutional corruption.
eBook
Phantom Billing, Fake Prescriptions, and the High Cost of Medicine
U.S. health care is a $2.5 trillion system that accounts for more than 17 percent of the nation’s GDP. It is also highly susceptible to fraud. Estimates vary, but some observers believe that as much as 10 percent of all medical billing involves some type of fraud. In 2009, New York’s Medicaid fraud office recovered $283 million and obtained 148 criminal convictions. In July 2010, the U.S. Justice Department charged nearly 100 patients, doctors, and health care executives in five states of bilking the Medicare system out of more than $251 million through false claims for services that were medically unnecessary or never provided. These cases only hint at the scope of the problem. In Phantom Billing, Fake Prescriptions, and the High Cost of Medicine, Terry L. Leap takes on medical fraud and its economic, psychological, and social costs. Illustrated throughout with dozens of specific and often fascinating cases, this book covers a wide variety of crimes: kickbacks, illicit referrals, overcharging and double billing, upcoding, unbundling, rent-a-patient and pill-mill schemes, insurance scams, short-pilling, off-label marketing of pharmaceuticals, and rebate fraud, as well as criminal acts that enable this fraud (mail and wire fraud, conspiracy, and money laundering). After assessing the effectiveness of the federal laws designed to fight health care fraud and abuse—the antikickback statute, the Stark Law, the False Claims Act, HIPAA, and the food and drug laws—Leap suggests a number of ways that health care providers, consumers, insurers, and federal and state officials can bring health care fraud and abuse under control, thereby reducing the overall cost of medical care in America.
eBook
Doubt is Their Product
In this eye-opening expose, David Michaels reveals how unscrupulous product-defense consultants have increasingly shaped and skewed the scientific literature, manufactured and magnified scientific uncertainty, and influenced policy decisions to the advantage of polluters and the manufacturers of dangerous products. He proves that our regulatory system is broken and offers concrete, workable suggestions for how it can be restored by taking the politics out of science and ensuring that concern for public safety, rather than private profits, guides our regulatory policy.
eBook
Prescriptions for Compliance with the Foreign Corrupt Practices Act: Identifying Bribery Risks and Implementing Anti-Bribery Controls in Pharmaceutical and Life Sciences Companies
The U.S. Foreign Corrupt Practices Act has become a focal point of enforcement efforts of the U.S. Department of Justice and U.S. Securities and Exchange Commission, as witnessed by the surge in the number of companies and individuals currently under investigation for, or that recently have settled charges of bribing foreign government officials to secure business advantages. This heightened level of law enforcement activity has particularly affected pharmaceutical and life sciences companies. For example, enforcement authonties currently are conducting an investigation involving payments made by the six leading manufacturers of orthopedic implants to physicians employed by government-owned hospitals outside the United States, while several well-known pharmaceutical companies are also targets of similar investigations. This Article examines from a practitioner's perspective the specific types and levels of risks that pharmaceutical and life sciences companies confront under the Foreign Corrupt Practices Act that, in some instances, have led to enforcement proceedings. The Article then addresses the elements of an effective Foreign Corrupt Practices Act compliance program to control the bribery nsks that arise from the complex and varied ways in which such companies interact with government regulators and customers. The Article provides practical advice on the compliance programs that should be considered by pharmaceutical and life sciences companies to control company-and country-specific bribery risks, particularly in light of the current enforcement environment. While these companies confront a number of unique risks, many of the insights and recommendations in the Article are relevant to companies in other industnes that operate in a global environment.
Journal Article
Corporate Saints and Sinners: The Effects of Philanthropic and Illegal Activity on Organizational Performance
This article utilizes a two-dimensional view of corporate social responsibility (CSR) to examine the relationships between corporate financial performance and experts' ratings of CSR. The two dimensions are compliance/noncompliance with society's minimal expectations (the law) and involvement/noninvolvement in praiseworthy or supererogatory behavior (philanthropic contributions). In this study, four groups of corporations are identified: \"saints\" (no crimes, high contributions); \"pharisees\" (no crimes, low contributions); \"cynics/repenters\" (crimes, high contributions); and \"sinners\" (crimes, low contributions). A survey of industry experts reveals that the saints and the cynics/repenters groups were rated significantly higher on CSR than the other two groups. Firms in the sinners group performed significantly poorer than the other three groups on two five-year financial performance measures. These results have important implications for the debate over the relationship between CSR and financial performance
Journal Article